Immune System Peptides

Three peptides. Three layers of immune defense. Your adaptive immune system, your innate frontline antimicrobial response, and the gut barrier where roughly 70% of your immune cells live each requires a different tool. Thymosin Alpha-1 (TA1), LL-37, and BPC-157 target one layer each, and the evidence behind them ranges from 40 years of human clinical trials to promising but early animal data. This guide explains what the research actually shows, what it doesn’t, and what accessing these peptides legally requires in 2026.

Key takeaways

• Thymosin Alpha-1 (TA1) has the strongest human evidence of any immune peptide: 11,000+ subjects across 30+ clinical trials, FDA orphan drug designation for four conditions, and pharmaceutical approval (Zadaxin) in 35+ countries. PeptideRx rates its evidence as Grade A.
• LL-37 is the only human cathelicidin — it kills bacteria, viruses, and fungi by disrupting their membranes, and bridges innate immune killing to adaptive immune memory. Human trial evidence remains limited; PeptideRx rates it Grade C.
• BPC-157 reinforces gut barrier integrity, which matters because approximately 70% of immune cells reside in gut-associated lymphoid tissue (GALT). Evidence is primarily from animal models; PeptideRx rates it Grade C.
• Injectable subcutaneous delivery is the only clinically validated route for systemic immune effects. Digestive enzymes break therapeutic peptides into amino acid fragments before they can reach the bloodstream intact.
• As of March 2026, TA1’s compounding status is in transition following an HHS announcement on February 27, 2026 indicating reclassification back to Category 1 is expected — but formal FDA documentation is not yet finalized. Verify current status at FDA.gov before obtaining.

Before you start Thymosin Alpha-1, LL-37, and BPC-157 are not FDA-approved for immune enhancement. All compounded peptide protocols require a valid prescription from a licensed physician, baseline lab evaluation, and ongoing medical supervision. Do not self-administer or source these compounds without a prescription.

What are immune system peptides?

Immune system peptides are short chains of amino acids typically 3 to 200 residues that regulate immune cell activity, kill pathogens directly, or protect the barrier tissues that form your body’s first line of defense.

They are smaller than antibodies and larger proteins, but complex enough to bind specific receptors and trigger precise immune responses. That specificity is what makes them clinically interesting and what distinguishes therapeutic peptides from the amino acids you get from food.

Three functional categories cover the peptides in this guide:

• Immunomodulatory peptides (Thymosin Alpha-1): Regulate T-cell and NK cell activity, modulate cytokine production, and restore immune balance in deficiency states.
• Antimicrobial peptides (LL-37): Kill bacteria, viruses, and fungi directly, and recruit immune cells to infection sites.
• Regenerative/barrier peptides (BPC-157): Strengthen intestinal epithelial integrity and support the gut-immune axis where most immune cells reside.

Natural vs synthetic production

TA1 is naturally produced by thymic epithelial cells. The thymus produces less of it as it shrinks with age – a process called thymic involution that begins in your 20s and accelerates after 40. Pharmaceutical TA1 (sold as Zadaxin in 35+ countries) is a synthetic replica of the same 28-amino acid sequence. Synthetic production enables standardized dosing and greater than 98% purity verification — something declining endogenous levels simply cannot provide.

LL-37 is produced by neutrophils, macrophages, and epithelial cells as part of innate immune defense. BPC-157 is derived from a sequence in gastric Body Protection Compounds. Pharmaceutical synthesis of both enables consistent dosing that the body’s natural production cannot match.

How immune peptides compare to antibodies

Property	Immune peptide	Antibody
Size	3–20 kDa	~150 kDa
Speed of action	Hours	Days to weeks for full response
Target specificity	Broad-spectrum immune modulation	Single antigen
Where produced	Naturally (thymus, skin, gut) or synthetic	B-cell secretion after antigen exposure
Where they act	Upstream — activate immune cells	Downstream — neutralize identified threats

Learn more about how immune peptides differ from conventional immunotherapy approaches.

How immune peptides work in the body

Each peptide operates through a different mechanism. Understanding all three explains why comprehensive immune protocols often combine them.

Key takeaways

• TA1 activates a TLR2/TLR9 signaling cascade in dendritic cells that matures CD4+, CD8+ T-cells, and NK cells — the core of adaptive immune response.
• LL-37 disrupts microbial membranes through direct pore formation and simultaneously recruits dendritic cells and neutrophils to the infection site, bridging innate to adaptive immunity.
• BPC-157 activates eNOS to reinforce intestinal tight junctions, preventing bacterial endotoxins from entering the bloodstream and chronically activating GALT-resident immune cells.

Thymosin Alpha-1: TLR activation cascade

TA1 binds Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9) on myeloid and plasmacytoid dendritic cells (Romani et al., 2004, PMID: 15001469). This binding activates NF-κB and IRF3 signaling pathways inside the dendritic cell, producing a cascade with five steps:

1. TA1 binds TLR2/TLR9 on dendritic cells
2. Dendritic cells activate NF-κB and IRF3 signaling
3. IL-2 and IFN-γ cytokines increase; TNF-α and IL-1β decrease
4. CD4+ helper T-cells, CD8+ cytotoxic T-cells, and NK cells mature and activate
5. Antibody response improves; pathogen clearance increases

The result: your adaptive immune system — the branch responsible for pathogen-specific responses and immune memory — functions more effectively, while the excessive inflammatory signals that cause collateral damage are dialed down.

LL-37: dual innate-to-adaptive bridge

LL-37 operates through two simultaneous actions.

First, its positively charged (cationic) structure interacts with the negatively charged membranes of bacteria, fungi, and enveloped viruses. LL-37 inserts into the microbial membrane and forms pores that cause the pathogen to fall apart. This membrane disruption mechanism works against MRSA, VRE, and Pseudomonas aeruginosa — including strains embedded in biofilms that resist conventional antibiotics (Simonetti et al., 2021, PMID: 34680791).

Second, LL-37 functions as a chemoattractant. It recruits dendritic cells and neutrophils to the infection site and activates antigen-presenting cells. That bridge from innate killing to adaptive memory formation is what distinguishes LL-37 from a simple antibiotic alternative.

BPC-157: gut barrier and GALT support

Body Protection Compound-157 (BPC-157) is a 15-amino acid gastric peptide that activates endothelial nitric oxide synthase (eNOS). eNOS activation promotes angiogenesis (new blood vessel formation) and collagen synthesis, strengthening the tight junctions between intestinal epithelial cells.

When those junctions break down, bacteria and endotoxins pass from the gut into the bloodstream — a state called increased intestinal permeability. The result is systemic inflammation that chronically consumes immune resources.

Approximately 70% of the body’s immune cells reside in gut-associated lymphoid tissue (GALT). Maintaining gut barrier integrity keeps GALT in a regulated state rather than a chronically activated, inflammatory one — which is the immune-relevant rationale for including BPC-157 in immune protocols.

Learn more about how GALT-resident immune cells are affected by gut barrier dysfunction.

Three classes of immune system peptides

Attribute	Thymosin Alpha-1 (TA1)	LL-37 Cathelicidin	BPC-157
Primary function	Adaptive immunity enhancement	Innate antimicrobial defense	Gut barrier and tissue repair
Structure	28 amino acids, 3,108 Da	37 amino acids	15 amino acids
Mechanism	TLR2/TLR9 → T-cell/NK activation	Membrane disruption + dendritic cell recruitment	eNOS activation → tight junction integrity
Clinical applications	Hepatitis B, cancer adjuvant, sepsis subgroups, vaccine enhancement	Resistant infections, wound healing	Gut integrity, GI repair
Standard clinical dose	1.6 mg SC twice weekly	Research stage	250–500 mcg/day
Evidence tier	Grade A — multiple human RCTs	Grade C — mechanistic and animal; emerging clinical	Grade C — animal and small pilot studies

Thymosin Alpha-1

TA1 is a 28-amino acid peptide (molecular weight 3,108 Daltons) cleaved from prothymosin-α, naturally produced by thymic epithelial cells. It targets adaptive immunity — the branch responsible for pathogen-specific responses and immune memory.

Clinical applications with human RCT evidence: chronic hepatitis B, cancer adjuvant therapy (melanoma, hepatocellular carcinoma), sepsis in specific subgroups (elderly and diabetic patients), and vaccine response enhancement in immunocompromised individuals.

Evidence: PeptideRx rates the evidence for Thymosin Alpha-1 as Grade A, based on multiple randomized controlled trials across 11,000+ subjects.

LL-37

LL-37 is a 37-amino acid cathelicidin — the only human member of this antimicrobial peptide family. It kills a broad spectrum of pathogens through membrane disruption and remains active against biofilm-embedded organisms that resist conventional antibiotics. Resistance development is substantially slower with LL-37 than with conventional antibiotic drugs (Simonetti et al., 2021).

Clinical interest centers on chronic infections, wound healing, and antibiotic-resistant bacterial situations. Human clinical trials remain limited compared to TA1’s evidence base. LL-37 is not yet available as a standardized prescription compound in the United States.

Evidence: PeptideRx rates the evidence for LL-37 as Grade C — strong mechanistic rationale and in vitro data; limited human RCT evidence.

BPC-157

BPC-157 is a synthetic 15-amino acid peptide derived from a sequence in gastric juice. Its primary immune-relevant function is maintaining intestinal epithelial integrity through eNOS activation and tight junction reinforcement. Three small human pilot studies exist as of March 2026 — none are controlled trials. All substantive evidence comes from animal models.

The rationale for its inclusion in immune protocols rests on the GALT connection: a leaky gut chronically activates immune cells, consumes immune resources, and generates systemic inflammation. Repairing the gut barrier addresses a root cause of immune dysregulation.

Evidence: PeptideRx rates the evidence for BPC-157 for immune support as Grade C.

Learn more about the differences between Grade A and Grade C evidence in peptide therapy.

Clinical applications and researched benefits

Key takeaways

• Hepatitis B is TA1’s best-documented application: 40.6% complete virological response vs 9.4% placebo in a 26-week RCT (Chien et al., 1998; n=98).
• The definitive TESTS Phase 3 sepsis trial (n=1,106) found no overall mortality benefit from TA1, though subgroup signals in patients aged 60+ and diabetics warrant dedicated follow-up trials.
• TA1 improved tumor response rates and overall survival trend in a 488-patient melanoma RCT (Maio et al., 2010), with no additional toxicity vs control.
• TA1 improved influenza vaccine antibody response in elderly men and improved hepatitis B vaccine seroconversion in hemodialysis patients who had previously failed to respond.

Chronic viral infections

Hepatitis B is TA1’s best-documented clinical application. Chien et al. (1998, PMID: 9581695) randomized 98 patients to 1.6 mg TA1 subcutaneous twice weekly for 26 weeks or placebo. The TA1 group achieved 40.6% complete virological response (clearance of HBV DNA and HBeAg) versus 9.4% in placebo (p=0.004). Liver histology improved significantly in the TA1 group.

For hepatitis C, Sherman et al. (1997, PMID: 9026482) tested TA1 1 mg twice weekly combined with lymphoblastoid interferon, producing 73% HCV RNA negativity at treatment completion. HCV treatment has since been superseded by direct-acting antivirals with substantially higher cure rates, so TA1’s role in hepatitis C is largely historical.

Cancer adjuvant therapy

Maio et al. (2010, PMID: 20194853) conducted a multicenter Phase II RCT enrolling 488 patients with metastatic melanoma. TA1 groups showed tumor response rates of 10–12% versus 4% in the control group. Median overall survival in TA1 groups reached 9.4 months versus 6.6 months in control (hazard ratio 0.80, p=0.08). No additional toxicity was observed in any TA1 arm.

More recent work by Wei et al. (2025) examined TA1 combined with lenvatinib and a PD-1 inhibitor for unresectable hepatocellular carcinoma, finding TA1 promoted M1 macrophage polarization that reversed tumor immunosuppression. This positions TA1 as a potential checkpoint inhibitor enhancer rather than a standalone cancer treatment.

Critical illness and sepsis — the full picture

TA1’s sepsis evidence is mixed, and presenting it accurately matters.

Wu et al. (2013, PMID: 23327199) conducted a multicenter RCT in 361 patients with severe sepsis. TA1 showed 28-day mortality of 26% versus 35% in placebo (relative risk 0.74, p=0.062) — a trend, not a statistically significant result.

The TESTS trial (Wu et al., 2025, PMID: 39814420) was the definitive Phase 3 study: 1,106 patients, 22 centers, double-blind, placebo-controlled. 28-day all-cause mortality was 23.4% in the TA1 group and 24.1% in placebo (hazard ratio 0.99, 95% CI 0.77–1.27, p=0.93). TA1 showed no overall mortality benefit in adults with sepsis.

A prespecified subgroup analysis identified possible differential effects: patients aged 60 and older (HR 0.81, 95% CI 0.61–1.09) and patients with diabetes (HR 0.58, 95% CI 0.35–0.99) showed signals of potential benefit. These findings require dedicated trials to confirm — they should not be used to justify general sepsis use.

For severe acute pancreatitis, a 2025 meta-analysis (Frontiers in Immunology, PMC: 12208829) pooled five RCTs across 706 patients and found TA1 improved CD4+ percentages, reduced C-reactive protein, and reduced infection rates versus controls.

Vaccine enhancement

Gravenstein et al. (1989) found TA1 augmented antibody response to influenza vaccine in elderly men. Carraro et al. (2012) found TA1 improved hepatitis B vaccine seroconversion in hemodialysis patients who had previously failed to respond — a population with known impaired vaccine immunity. Both findings support TA1 as an adjuvant for immunocompromised individuals who respond poorly to standard vaccination.

Learn more about how TA1 compares to other vaccine adjuvant strategies in immunocompromised populations.

Oral supplements vs injectable therapy: why delivery route determines outcome

Most immune peptide supplements sold without a prescription are oral products — capsules or powders marketed around TA1, LL-37, colostrum-derived peptides, or similar compounds. Oral delivery does not produce systemic immune effects with these peptides.

Here’s why. Stomach acid (pH 1.5–3.5) begins denaturing peptide structure upon ingestion. Digestive enzymes — pepsin in the stomach, then trypsin and chymotrypsin in the small intestine — systematically cleave peptide bonds. TA1’s 28 amino acids, LL-37’s 37 amino acids, and BPC-157’s 15 amino acids are broken down into individual fragments before reaching the bloodstream.

Those fragments lack the three-dimensional receptor-binding structures required for TLR activation, membrane disruption, or eNOS stimulation. At best, 5–15% of an oral peptide dose may reach systemic circulation — and not as intact therapeutic molecules.

The result: oral “immune peptide supplements” deliver amino acids that are available from any dietary protein source. The immune-modulating structure is gone.

Subcutaneous injection bypasses the gastrointestinal tract entirely. Intact TA1 molecules enter the bloodstream via capillary absorption with bioavailability of 95–100%. TA1 reaches peak serum concentration approximately 2 hours post-injection, with a half-life of approximately 2 hours — no drug accumulation, predictable dosing intervals. Every clinical trial demonstrating TA1’s efficacy used subcutaneous injection. No human studies support oral administration for systemic immune effects.

Factor	Subcutaneous injection	Oral supplement
Bioavailability	95–100%	5–15%
Intact peptide reaches bloodstream	Yes	No
Clinical trial validation	All RCTs used this route	Zero RCTs for systemic immune effects
Onset	Peak at ~2 hours (TA1)	No systemic therapeutic onset
Dosing precision	Confirmed by pharmacokinetics	Unpredictable

Learn more about subcutaneous injection technique and what to expect from your first administration.

Thymosin Alpha-1: clinical protocol and dosing

Standard dosing

Clinical trials established 1.6 mg subcutaneous injection twice weekly (for example, Monday and Thursday) as the standard protocol for chronic conditions including hepatitis B and cancer adjuvant therapy. For acute illness such as sepsis, the protocol used in trials was 1.6 mg subcutaneous every 12 hours for 7 days.

All dosing information below reflects published research protocols, not prescribing recommendations. Consult a licensed physician for an individualized protocol.

Reconstitution: A standard 10 mg TA1 vial reconstituted with 3.0 mL bacteriostatic water yields 3.33 mg/mL. For a 1.6 mg dose, draw 0.48 mL — equivalent to 48 units on a U-100 insulin syringe.

Storage: Refrigerate reconstituted TA1 at 2–8°C (36–46°F). With bacteriostatic water: use within 28 days. With sterile water (no preservative): use within 24–48 hours. Do not freeze reconstituted solution — freezing damages peptide structure.

Injection sites: Abdomen (2 inches from navel), anterior thighs, posterior upper arms. Rotate systematically, maintaining at least 1 inch from the previous site.

Four-phase medical protocol

All compounded peptide therapy requires a licensed physician’s evaluation, prescription, and ongoing supervision.

Phase	Timing	Key activities
Initial assessment	Week 0	Full medical history review, contraindication screening, baseline labs (lymphocyte count, CD4+/CD8+ ratio, NK cell activity, CRP, ESR, liver and kidney function)
Loading	Weeks 1–4	1.6 mg TA1 twice weekly; injection training covering reconstitution, sterile technique, site rotation, and sharps disposal
Optimization	Weeks 5–12	Follow-up labs at 4–6 weeks; dosing adjustments based on immune marker response and tolerability
Maintenance	Month 4+	Ongoing twice-weekly dosing; quarterly lab monitoring and treatment goal reassessment

Learn more about what baseline immune labs reveal before starting a TA1 protocol.

Safety, side effects, and contraindications

Key takeaways

• A 2024 review (Dinetz and Lee, PMID: 38308608) assessed 11,000+ subjects across 30+ trials. The most common side effect is mild injection-site reactions in fewer than 10% of patients, resolving within 24–48 hours.
• No organ toxicity affecting liver, kidney, or cardiac function has been documented across 40+ years of clinical use.
• Organ transplant recipients on immunosuppression should not use TA1 — its immune-enhancing effects carry a theoretical rejection risk.
• Adverse effects in trials combining TA1 with interferon-alpha are almost entirely attributable to interferon, not TA1.

Route	Common adverse effects	Serious risks	Mitigation
Subcutaneous injection (TA1)	Injection-site erythema, tenderness (<10%)	Rare allergic reaction	Sterile technique, site rotation
Intramuscular injection	Pain, bruising at site	Injection-site infection	Proper needle length, trained technique
Nasal (LL-37, experimental)	Nasal irritation, headache	Rare	Dose reduction
Oral (BPC-157, GI-specific only)	Mild GI upset	Unpredictable systemic absorption	Start low, physician guidance

Contraindications

Organ transplant recipients on immunosuppression (tacrolimus, cyclosporine): TA1’s immune-enhancing effects carry a theoretical rejection risk. Do not use.

Pregnancy: Insufficient human safety data. Avoid.

Active autoimmune flare: TA1 stimulates the immune system and may worsen active flares of rheumatoid arthritis, lupus, or multiple sclerosis. Use only during remission, under specialist supervision.

Known hypersensitivity to TA1: Discontinue immediately if allergic reaction occurs.

Active malignancy or recent remission (BPC-157): BPC-157’s pro-angiogenic mechanism (promoting new blood vessel formation) requires oncologist review before use in patients with cancer history.

Learn more about how to recognize and manage injection-site reactions from subcutaneous peptide administration.

Regulatory status and access (2026)

US regulatory status

Thymosin Alpha-1 is not FDA-approved for any general-use indication in the United States. The FDA has granted orphan drug designation for four conditions — chronic hepatitis B, DiGeorge syndrome, hepatocellular carcinoma, and malignant melanoma — recognizing therapeutic potential in serious, rare conditions.

Compounding history: TA1 was available through licensed 503A compounding pharmacies until late 2023, when the FDA moved it to Category 2 (“Do Not Compound” status). On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 Category 2-restricted peptides would return to Category 1, restoring legal compounding access. As of March 2026, formal FDA regulatory documentation confirming this reclassification has not been published.

Important: Verify current TA1 compounding status at FDA.gov before obtaining. Do not rely on vendor claims about regulatory status.

International approvals

Thymalfasin (Zadaxin) — the pharmaceutical TA1 product — is approved in more than 35 countries including China, South Korea, Thailand, Brazil, Argentina, Saudi Arabia, UAE, Russia, Italy, and the Philippines. These approvals cover chronic hepatitis B and C treatment, cancer support, and immune deficiency. Zadaxin is not approved by the FDA, Health Canada, or most Western European regulatory agencies.

How to access compounded TA1 legally

Three requirements apply:

1. A valid prescription from a licensed physician (MD, DO, or NP with prescriptive authority)
2. A 503A state-licensed compounding pharmacy, preferably PCAB-accredited
3. A certificate of analysis confirming greater than 98% purity by HPLC and passing sterility testing

Do not obtain TA1 from vendors marketing it as a “research chemical” or selling without a prescription requirement. These products carry no quality control guarantee or legal protection.

Learn more about how to verify a compounding pharmacy’s 503A licensure and PCAB accreditation.

Alternatives

Option	Mechanism	Evidence tier	Relationship to peptides
Thymosin Beta-4 (TB-500)	Actin regulation — tissue repair, angiogenesis	Grade C	Different peptide, different indication; not interchangeable with TA1
Interferon-alpha	Direct antiviral, immune stimulation	Grade A (HBV/HCV)	More side effects; mostly replaced by direct-acting antivirals for HCV
Checkpoint inhibitors	Block PD-1/CTLA-4; restore T-cell cancer killing	Grade A (cancer)	Different mechanism; immune toxicity risk; TA1 may enhance their efficacy
Vitamin D (therapeutic dose)	Vitamin D receptor modulation — innate and adaptive immunity	Grade B	Oral, lower cost; correct deficiency before adding injectable peptides
Zinc	Thymulin cofactor; T-cell enzyme support	Grade B	Oral, foundational; not equivalent to TA1 for immune deficiency states
Probiotics	Gut microbiome modulation; GALT immune support	Grade B	Complementary to BPC-157; targets a different gut-immune mechanism

Thymosin Beta-4 vs Thymosin Alpha-1 — not the same peptide

These two peptides share a name prefix and nothing else of clinical relevance. TA1 is 28 amino acids derived from prothymosin-α and targets adaptive immune enhancement via TLR signaling. TB-500 (Thymosin Beta-4) is 43 amino acids derived from an actin-binding protein and targets tissue repair and wound healing. They come from different precursor proteins, use different mechanisms, and serve different therapeutic purposes.

They are not interchangeable — though they can theoretically be combined, no clinical combination trial currently exists.

Non-peptide immune foundations

Vitamin D at therapeutic levels (maintaining serum 25-OH-D at 50–80 ng/mL), zinc sufficiency, and evidence-based probiotic strains form the nutritional foundation of immune support. These support but do not replicate what TA1 achieves through T-cell and NK cell activation via TLR signaling. Correct foundational deficiencies before adding injectable peptides.

Learn more about how to sequence foundational immune support with peptide therapy.

The bottom line

Thymosin Alpha-1, LL-37, and BPC-157 address three separate but connected layers of immune function — and their evidence bases are vastly different. TA1 is the most clinically validated immune peptide in existence: Grade A evidence, 40 years of human data, and pharmaceutical approval in over 35 countries. LL-37 and BPC-157 carry Grade C ratings — mechanistically sound, but with human clinical evidence that remains preliminary. Subcutaneous injection is the only validated route for systemic immune effects; oral peptide supplements deliver amino acids, not intact therapeutic molecules. If you’re considering peptide therapy for immune support, start with a licensed physician who can evaluate your immune markers, screen for contraindications, and determine whether the evidence supports your specific situation.

Frequently Asked Questions

Can immune peptides prevent illness during flu season?

Possibly, with appropriate context. Gravenstein et al. (1989) found TA1 improved antibody response to influenza vaccine in elderly men. Prophylactic use of 1.6 mg TA1 twice weekly starting 4–8 weeks before flu season may support T-cell and NK cell readiness. TA1 is not a replacement for influenza vaccination — it is a potential adjuvant to vaccination. Consult a licensed physician for a seasonal protocol.

Are immune system peptides safe for long-term use?

Yes, based on available evidence — with appropriate monitoring. Dinetz and Lee (2024, PMID: 38308608) reviewed 11,000+ subjects across 30+ clinical trials. Trials ran as long as 6–12 months continuously without organ toxicity signals. Doses up to 16 mg for 12 months showed no significant adverse events in the December 2024 FDA PCAC safety review. The most common side effect remains mild injection-site reactions in fewer than 10% of patients. Controlled studies beyond 12 months are limited; real-world use in 35+ countries over 40+ years has not produced major adverse event signals. Quarterly lab monitoring during maintenance is standard practice.

What is the difference between Thymosin Alpha-1 and Thymosin Beta-4?

They are completely different peptides. TA1: 28 amino acids from prothymosin-α, targets immune modulation via T-cell and NK cell activation, used for viral infections, cancer support, and immune deficiency. TB-500 (Thymosin Beta-4): 43 amino acids from an actin-binding protein, targets tissue repair, wound healing, and angiogenesis. Different precursor proteins, different mechanisms, different therapeutic purposes. They are not interchangeable.

Do immune peptides work for autoimmune conditions?

The evidence is insufficient to make a clear recommendation. TA1 modulates rather than uniformly stimulates the immune system — it promotes balance by upregulating IL-2 and IFN-γ while downregulating excessive TNF-α and IL-1β. This modulatory mechanism has generated interest in rheumatoid arthritis and multiple sclerosis, but large human RCTs in autoimmune conditions do not yet exist. TA1 should not be used during active autoimmune flares, where immune stimulation may worsen symptoms. Use in remission only, under specialist supervision.

How long before results appear?

Timelines vary by goal. For acute infections, immune marker changes (lymphocyte counts, NK cell activity) appear within 7 days per sepsis study data. For chronic hepatitis, viral clearance is assessed at 26–52 weeks. For general immune optimization, measurable immune marker improvements appear at 4–8 weeks; reduced infection frequency is sometimes reported within 2–4 weeks. For vaccine adjuvant use, enhanced antibody response occurs within 2–4 weeks. Lab monitoring at the 4–6 week mark provides objective data beyond subjective experience.

Can I take immune peptides if I have cancer?

TA1 is not contraindicated for cancer — it has been studied as a cancer treatment. Maio et al. (2010) enrolled 488 metastatic melanoma patients; TA1 showed no tumor-promoting effect and a survival trend favoring the TA1 groups. TA1 combined with checkpoint inhibitors may enhance their efficacy through immune surveillance restoration. However, individuals with active cancer must obtain oncologist approval before starting any peptide protocol — not due to TA1-specific concerns, but to coordinate with existing chemotherapy and radiation schedules.

How do I store reconstituted immune peptides?

Reconstituted TA1 stores at 2–8°C (36–46°F) immediately after mixing, protected from light and heat. With bacteriostatic water: use within 28 days. With sterile water (no preservative): use within 24–48 hours. Do not freeze reconstituted solution — freezing damages peptide structure. Lyophilized (unreconstituted) powder stores at refrigerator temperature (2–8°C) short-term or at -20°C for long-term storage, stable for 12–24 months in original sealed vials.

Considering peptide therapy for immune support? A licensed physician can review your immune labs, screen for contraindications, and discuss whether the evidence supports a protocol for your specific situation.

References

1. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2004. PMID: 15001469
2. Dinetz E, Lee E. Comprehensive review of the safety and efficacy of Thymosin Alpha 1 in human clinical trials. Altern Ther Health Med. 2024;30(1):6–12. PMID: 38308608
3. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998. PMID: 9581695
4. Sherman KE, Sehgal P, Creager RL, et al. Combination therapy with thymosin alpha 1 and lymphoblastoid interferon in chronic hepatitis C. Gut. 1997. PMID: 9026482
5. Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010. PMID: 20194853
6. Wu J, Zhou L, Liu J, et al. Effect of thymosin alpha 1 on mortality in patients with severe sepsis: a multicenter, randomized, controlled trial. Crit Care Med. 2013. PMID: 23327199
7. Wu J, et al. Efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial. BMJ. 2025. PMID: 39814420
8. Simonetti O, Cirioni O, Goteri G, et al. Efficacy of cathelicidin LL-37 in an MRSA wound infection mouse model. Antibiotics (Basel). 2021;10(10):1210. PMID: 34680791
9. Tan Y, Yang J, Ma Y, et al. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front Immunol. 2025. PMC: 12208829
10. Bhattacharjya S, Zhang Z, Ramamoorthy A. LL-37: structures, antimicrobial activity, and influence on amyloid-related diseases. Biomolecules. 2024;14:320.
11. Dominari A, Hathaway D III, Pandav K, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9:67–78. PMC: 7747025
12. Gravenstein S, et al. Augmentation of influenza antibody response in elderly by thymosin alpha 1. 1989.
13. Carraro G, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine. 2012;30(6):1170–80.

Disclaimer: This article is for educational purposes only. Thymosin Alpha-1, LL-37, and BPC-157 are not FDA-approved for the indications discussed. Compounded peptides require a valid prescription from a licensed physician and must be sourced from a licensed compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This content does not constitute medical advice. PeptideRx does not provide medical advice, diagnosis, or treatment. Evidence grading criteria are working definitions pending formal review.